INTERVENTIONAL CARDIOLOGY
Our Interventional Cardiology program leads and contributes to cutting-edge clinical research focused on improving the diagnosis, treatment, and long-term outcomes of patients with cardiovascular disease. We are particularly invested in addressing gaps in care for underserved populations, enhancing risk stratification, and evaluating the safety and efficacy of novel therapeutics and technologies. Through collaborative, data-driven research, we aim to shape the future of interventional cardiology and deliver better care for patients at every stage of heart disease.
Research Projects
COMET-HF Study
PI: Dr. Wael Abuzeid
This multicenter, double-blind, randomized, placebo-controlled trial is evaluating the efficacy and safety of omecamtiv mecarbil in patients with symptomatic heart failure with severely reduced ejection fraction (HFrEF). The primary goal is to determine whether omecamtiv mecarbil reduces the risk of a composite outcome that includes cardiovascular death, first heart failure event, LVAD implantation, cardiac transplantation, or stroke. Participants are randomized 1:1 to receive either the investigational drug or placebo. The event-driven study will conclude once 850 patients have experienced a qualifying heart failure event or cardiovascular death. An interim analysis will be conducted after approximately 570 events to assess futility and efficacy. Estimated study duration: Up to 3 years.
Dal-GenE-2: Targeted Cardiovascular Prevention Trial
PI: Dr. Wael Abuzeid
Dal-GenE-2 (Dal-302) is a Phase III, randomized, double-blind, placebo-controlled study evaluating whether dalcetrapib can reduce fatal and non-fatal myocardial infarction (MI) in 2,000 patients with a recent acute coronary syndrome (ACS) and the AA genotype at rs1967309 in the ADCY9 gene. Building on the promising results of the original Dal-GenE trial—which showed a 21% relative risk reduction (RRR) in global participants and 45% RRR in North American patients—this confirmatory trial is coordinated by the Montreal Health Innovations Coordinating Centre (MHICC). Recruitment began in Q3 2023, with interim analysis expected in 2026 and study completion by 2027.
Canadian SCAD Study: Understanding Outcomes and Informing Future Trials
PI: Dr. Joe Abunassar
This large, prospective, multicenter Canadian study aims to better understand the natural history of Spontaneous Coronary Artery Dissection (SCAD) based on predisposing arteriopathies and treatment strategies. The goal is to assess short- and long-term cardiovascular (CV) outcomes and inform the design of future randomized controlled trials. SCAD is a poorly understood and underdiagnosed cause of myocardial infarction (MI), cardiac arrest, and sudden death, especially in young women without conventional CV risk factors. It is often misdiagnosed due to the limitations of coronary angiography, the current diagnostic standard. This study seeks to close critical gaps in knowledge and guide future evidence-based treatment approaches.
COMPLETE-2: Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease
PI: Dr. Wael Abuzeid
COMPLETE-2 is a prospective, multi-centre, randomized controlled trial comparing a strategy of physiology-guided complete revascularization to angiography-guided complete revascularization in patients with acute ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI) and multivessel coronary artery disease (CAD) who have undergone successful culprit lesion Percutaneous Coronary Intervention (PCI). COMPLETE-2 OCT is a large scale, prospective, multi-centre, observational, imaging study of patients with STEMI or NSTEMI and multivessel CAD in a subset of eligible COMPLETE-2 patients. Study objectives: To determine whether a strategy of physiology-guided complete revascularization is non-inferior to a strategy of angiography-guided complete revascularization on the efficacy composite outcome of cardiovascular (CV) death, new myocardial infarction (MI) or ischemia-driven revascularization (IDR). To determine whether a physiology-guided complete revascularization strategy is superior to an angiography-guided complete revascularization strategy in reducing the safety composite outcome of clinically significant bleeding, stroke, stent thrombosis or contrast-associated acute kidney injury.